

doi: 10.13241/j.cnki.pmb.2019.20.011

一例少见青少年T幼淋巴细胞白血病的病例报道及文献回顾*

常子维¹ 李秋红² 朱华锋¹ 冯苗娟¹ 苏小丽¹侯丽萍¹ 高山¹ 于书春¹ 田志强¹ 赵亚萍¹ 高广勋^{1△}

(1 空军军医大学西京医院血液科 陕西 西安 710032; 2 空军军医大学西京医院儿科 陕西 西安 710032)

摘要 目的: 报道一例少见幼年幼淋巴细胞白血病(T-PLL)患者的病例资料及诊疗过程,并通过文献复习总结了T-PLL的临床特点和诊疗措施。**方法:** 对病例资料进行对比分析,同时通过文献回顾研究T-PLL的特点及发生、发展及诊疗情况。**结果:** 本病例为少见青少年型幼淋巴细胞白血病,细胞以成熟小淋巴细胞为主,特征免疫表型为CD7⁺CD5⁺CD4⁺CD8⁺CD3⁺,无染色体异常,有TCR基因重排。**结论:** T-PLL病例具有多态性及复杂性,在临床诊断中需要密切联系临床特点及实验室诊断,综合判断疾病情况,做出最优治疗方案。

关键词: 幼淋巴细胞白血病(T-PLL); 免疫表型; 临床特点及实验室诊断

中图分类号: R733.7 文献标识码: A 文章编号: 1673-6273(2019)20-3849-04

Diagnosis and Treatment of a Rare Adolescent T-cell Prolymphocytic Leukemia and Literature Review*

CHANG Zi-wei¹, LI Qiu-hong², ZHU Hua-feng¹, FENG Miao-juan¹, SU Xiao-li¹,HOU Li-ping¹, GAO Shan¹, YU Shu-chun¹, TIAN Zhi-qiang¹, ZHAO Ya-ping¹, GAO Guang-xun^{1△}

(1 Department of hematology, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi, 710032, China;

2 Department of pediatrics, Xijing Hospital, Air Force Military Medical University, Xi'an, Shaanxi, 710032, China)

ABSTRACT Objective: To report a rare type of adolescent of T-cell Prolymphocytic Leukemia (T-PLL), and summarize the clinical features and diagnostic measures of T-PLL through reviewing the literatures. **Methods:** The clinical data of a rare type of adolescent of T-PLL was analyzed. The characteristics, occurrence, development and diagnosis and treatment of T-PLL were studied through literature review. **Results:** This case is a rare juvenile lymphoblastic leukemia. Most of the cells are mature small lymphocyte. The characteristic immunophenotype is CD7⁺CD5⁺CD4⁺CD8⁺CD3⁺. There is no chromosomal abnormality and TCR gene rearrangement positive. **Conclusions:** T-PLL has the characteristics of polymorphism and complexity. The clinical characteristics and laboratory diagnosis should be closely linked in clinical diagnosis, and disease conditions should be judged comprehensively to make the best treatment plan.

Key words: T-cell Prolymphocytic Leukemia (T-PLL); Immune phenotype; Clinical characteristics and laboratory diagnosis

Chinese Library Classification(CLC): R733.7 Document code: A

Article ID: 1673-6273(2019)20-3849-04

前言

T幼淋巴细胞白血病(T-PLL)是一种少见类型的淋巴细胞白血病,属于胸腺后T淋巴细胞肿瘤^[1],只占成熟淋巴细胞白血病的2%^[2-4],欧美发病较多,国内少见。T-PLL具有独特的细胞形态、免疫表型、细胞遗传学及分子生物学特征^[5],以外周血异常淋巴细胞比例增高、病情进展迅速、侵袭性强、全身肝脾淋巴结多发肿大、对化疗药物不敏感、生存期短^[6,7],部分病例有皮肤损害、浆膜腔积液及神经系统损害为主要特点^[8,9]。T-PLL30岁以上发病^[10],老年人为主,平均年龄为65岁^[11,12],青少年少见。本病不同病例临床症状及实验室检查存在异质性,从而导致疾病的诊断及鉴别诊断相对困难,临床治疗方案的选择不尽相

同。本病的本质还需要进一步探究,选择合适的临床及实验室指征,为治疗提供帮助^[13]。本病在报道中以中老年人为主,属于成熟淋巴细胞增殖性疾病,罕见发生于青少年^[12]。本文将报道一例13岁的T-PLL患者的诊疗过程,通过文献回顾,比较青少年型T-PLL和中老年型的异同点。

1 资料与方法

1.1 病例资料

患者,男,13岁,2017年五月上旬无明显诱因出现发热,体温最高38℃,无寒战畏冷,无咳嗽咳痰。5月7日就诊于当地三甲医院,给予消炎治疗后体温下降,但维持不佳,停药后反复,且随后出现腹痛,无腹泻,血常规示:白细胞计数4.2×10⁹/L;血

* 基金项目:国家自然科学基金项目(30900639);陕西省自然科学基金项目(2014JM2-8161);吴阶平医学基金项目1项(320.6750.13276)

作者简介:常子维(1986-),男,大学本科,主治医师,主要研究方向:白血病免疫分型,E-mail: czw287763145@163.com

△ 通讯作者:高广勋,男,博士,副主任医师,主要研究方向:血液病诊断与治疗,E-mail:gaoguangxun@fmmu.edu.cn,电话:02984775199

(收稿日期:2019-02-28 接受日期:2019-03-23)

红蛋白 126 g/L; 血小板计数 $147 \times 10^9/L$, 腹部 B 超示: 颈部、肠系膜多发淋巴结肿大, 肝脾轻度肿大, 乳酸脱氢酶 275IU/L, 肝肾功能正常, 外周血涂片淋巴细胞占 96%。5月 18 日复查血常规: 白细胞计数 $93.89 \times 10^9/L$; 淋巴细胞比例 76.7%。给予抗感染、激素治疗, 患者体温正常, 淋巴结缩小, 腹痛消失, 为进一步治疗于 5 月 22 日入住我院, 血常规示: 白细胞 $35.45 \times 10^9/L$, 血红蛋白 122 g/L, 血小板计数 $221 \times 10^9/L$, 行实验室检查。

1.2 细胞形态学及免疫

髂后上棘穿刺抽取骨髓液制作骨髓涂片用于形态学、免疫学检测, 同时采左手无名指末梢血制备血片, 骨髓片分类 250 个有核细胞, 血片分类 100 个有核细胞(有核红细胞除外), 免疫表型检测抗体为 CD4、CD8、CD3、TCR、CD34、CD33、CD13、CD117、HLA-DR、cCD3、cCD79a、cMPO、CD7、CD2、CD56、CD19、TDT, 流式细胞仪及相关检测抗体均购自美国贝克曼库尔特公司, 细胞膜抗体表达以大于 20% 为阳性表达, 膜内抗体表达以大于 10% 为阳性表达, "c" 代表细胞内。

1.3 荧光原位杂交技术(FISH)分析

取骨髓液清洗两遍, 弃上清, 加 KCL 水浴 20 min, 加冰醋酸 2 mL 固定、制片, 干燥后加荧光探针, 探针为购自广州安必平医药科技股份有限公司的白血病相关基因检测试剂盒, 用购自美国 ThermoBrite 公司的荧光原位杂交仪杂交, 荧光显微镜阅片, 计数 200 个细胞, 阳性细胞大于 4% 为阳性。

1.4 RT-PCR 及二代测序

取乙二胺四乙酸二钾(EDTA-2K)抗凝剂的骨髓液, 抽提 RNA, 用白血病相关融合基因检测试剂盒进行逆转录及扩增,

以上试剂均购自上海睿昂生物技术公司, PCR 仪购自美国安捷伦公司。结果判断以扩增 20 个循环起跳为阳性; 测序仪购自美国 ABI 公司。

2 结果

骨髓片形态学特点: 成熟淋巴细胞 75.6%, 幼淋巴细胞占 6.4%, 成熟淋巴细胞形态规则, 核染色质聚集, 核质比高, 未见核仁, 幼淋巴细胞形态规则, 核染色质聚集, 可见大而圆的 2-3 个核仁, 化学染色髓过氧化物酶(POX)阴性, 糖原(PAS)散在阳性。外周血片幼淋巴细胞占 14%(图 A), 细胞胞体小、形态规则染色质聚集浓染。骨髓活检显示满片成熟规则小淋巴细胞(图 B)。免疫分型结果为 CD7⁺CD5⁺CD4⁺CD8⁺CD3⁺, 其他检测抗体均阴性。FISH 探针检测 14q11-q32, inv(14)(qll;q32), inv(14)(qll;q32), 8q 三体均阴性。PCR 检测出 TCR 基因重排(图 C), 根据 WHO 标准, 确诊为 T-PLL。由于患者精神佳, 皮肤黏膜未见出血点, 对症治疗后, 患者出院, 未进行特殊治疗, 至六月底复查血常规白细胞波动在 $35.45-50.6 \times 10^9/L$ 。7 月 1 日白细胞为 $19.32 \times 10^9/L$, 7 月 4 日白细胞为 $17.84 \times 10^9/L$, 8 月 23 日, 患者再次入院, 患者一般状况良好, 无特殊不适, 白细胞计数 $9.85 \times 10^9/L$, 血小板计数 $203 \times 10^9/L$, 血红蛋白 119 g/L。虽然未行特殊治疗肿大淋巴结缩小, 外周血白细胞明显减低, 但外周血淋巴细胞比例一直维持在 90% 以上, 为控制病情, 给予 COP 方案化疗, 具体环磷酰胺 0.6g d1; 长春新碱 1 mg d1; 地塞米松 8 mg d1-5, COP 化疗顺利, 无恶性呕吐, 未诉特殊不适, 后续按照计划复查, 用药, 随访一直良好。




图 1 骨髓涂片、骨髓活检细胞形态及 TCR 基因测序图谱图

Fig.1 Bone marrow smear, bone marrow biopsy cell morphology and TCR gene sequencing map

注: A 为外周血小淋巴细胞, 染色质聚集、浓染。B 为骨髓活检, 形态规则的小淋巴细胞。C 为 TCR 基因 BC(D β -J β)297.66 片段重排。

Note: Fig. A is a small lymphocyte in peripheral blood. Chromatin is aggregated and strongly stained. Fig. B is a small lymphocyte with regular morphology in bone marrow biopsy. Fig. C is a rearrangement of BC (D β -J β) 297.66 fragment of TCR gene.




图 2 流式细胞术免疫分型散点图

Fig.2 Flow cytometry scatter plot of immunophenotyping

注:D 为抗体 CD4/CD8 双参数散点图。E 为抗体 CD3/CD8 双参数散点图。F 为抗体 CD2/CD5 双参数散点图，
G 为抗体 CD3/CD8 双参数散点图。

Note: Fig. D is a two-parameter scatter plot of antibody CD4/CD8. Fig. E is a two-parameter scatter plot of antibody CD3/CD8.
Fig.F is double-parameter scatter plot of antibody CD2/CD5 and Fig.G is double-parameter scatter plot of antibody CD3/CD8.

3 讨论

T-PLL 是一种少见类型的主要发生在成人的淋巴细胞白血病, 病情发展迅速, 患者肝脾淋巴结肿大, 外周血淋巴细胞比例增高, 部分患者伴有皮肤或精神损害, 病程一年左右^[6, 14-15]。幼稚淋巴细胞呈中等大小, 胞核规则或不规则, 核染色质浓集, 具有明显核仁, 胞质可见一些强嗜碱性突起^[16]。但也有一小部分病例外周血以成熟小淋巴细胞为主, 只有电子显微镜可见的核仁, 核染色质聚集粗糙, 肿瘤细胞相对温和, 病情发展缓慢, 对化疗药物敏感, 这些病例最早被称为 T-CLL(慢性 T 淋巴细胞白血病)。直到 2008 年, WHO 将典型 T-PLL 和 T-CLL 合并, 统称为 T-PLL^[17, 18], 因为大多数病例两者有着相同的临床表现及基因表型, 相似的治疗手段, 共同的耐药特点和短暂的生存期, 但一直以来的争论并没有减少^[19, 20], 各个学者的观点也不尽相同, 有报道认为应该恢复 T-CLL^[21], 因为 T-CLL 属于小淋巴细胞惰性肿瘤, 病情发展缓慢, 对化疗药物敏感, 生存期长, 如果按照 T-PLL 进行大剂量化疗, 会导致过度治疗, 减少生存质量

和生存期。Samuel Adediran, MD 等^[22] 报道了一例 78 岁的 T-PLL 患者, 最初外周血及骨髓淋巴细胞为成熟小细胞, 染色质聚集浓缩, 未见核仁, 全身未见淋巴结肿大, 也没有肝脾肿大, 免疫分型为 CD3(+)/CD4(+)/CD5(+)/CD8(-), 染色体核型为 45,X,-Y^[18], XY^[2], 在确诊后 7 年内没有任何症状, 也没有进行治疗, 18 年后才出现肝脾淋巴结肿大, 严重腹水, 外周血高白细胞, 给予一个疗程阿珠伦单抗治疗, 肝脾淋巴结缩小, 白细胞基本恢复正常, 但腹水没有改善, 患者健康状况不佳, 最后死亡。但也有报道持不同意见, 认为应该保持 WHO 分型的 T-PLL 和 T-PLL-SV^[23](小细胞性 T-PLL), 因为 T-PLL-SV 的独特特性并不绝对, 有些被认为是发生在儿童的惰性肿瘤, 结果发展很迅速, 浸润性强, 对化疗药物不敏感, 预后差, 生存期短^[6]。T-PLL 也可能有 T-PLL-SV 的特点, T-PLL 是侵袭性的, 但也有明显核仁的 T-PLL 是进展缓慢的, 呈惰性特点, 也有些病例等到确诊以后已经过了惰性期, 而呈现浸润发展, 所以 WHO 的 T-PLL 和 T-PLL-SV 的分型方法是适当的^[23]。部分文献认为疾病的惰性状态只是前期状态, 等发展为急进状态和典型 T-PLL 的疾病

特点、生存期没有差异^[24]。由于 T-PLL 病例少,缺少系统性研究,以往报道中主要是个案分析,而且基本都是发生在三十岁以上的成年人^[25]。查阅近年国内外文献,我们发现只有 Bryan Mitton 等^[11]报道了一例 16 岁的青少年病例,此患者伴随脊柱侧弯,存在神经系统症状,化疗无法耐受,最后干细胞移植。我们报道的是一例 13 岁男性病例,这是我们查询到文献报道 T-PLL 最小年龄,以成熟的小细胞为主,胞体规则,核染色质粗糙、聚集,免疫分型为 CD5⁺CD4⁺CD8⁺CD3⁺CD7,大多数情况下,T-PLL 大部分 CD2、CD3、CD7、CD45 阳性^[26,27],CD4⁺/CD8⁺^[28,29],CD4⁺/CD8⁺ 只发生在少数病例^[30,31],检出 TCR 异常基因重排,淋巴结及肝脾轻度增大,临床症状轻,在未采取化疗情况下,外周血淋巴细胞进行性减低,最后到恢复到正常范围,这可能是细胞恶性程度较低,部分对抗生素也敏感,为了防止肝脾淋巴结进一步扩大而开始 COP 方案化疗,一个疗程后缓解,患者精神佳,后续按照计划复查,用药,随访一直良好。

总之,T-PLL 是一种少见病例,发生于青少年的病例更少,还需要更多临床资料进一步研究^[24]。目前,根据形态学、免疫学等方法很难确定肿瘤为惰性还是侵袭性,如果是惰性大剂量化疗会过度治疗从而进一步减少患者生存质量,如果为侵袭性的而选择消极化疗,会延误病人病情,尤其青少年,对药物耐受性差,病情发展迅速,需要准确判断疾病的性质,以提供最恰当的治疗方案。以后的研究可以在分子生物学和染色体方面寻找与疾病的相关特性。这方面已经有些报道,但还需要时间验证和扩大范围研究。

参考文献(References)

- [1] Keisuke Kawamoto, Hiroaki Miyoshi, Eriko Yanagida, et al. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified[J]. Eur J Haematol, 2017, 98: 459-466
- [2] Umit Yavuz Malkan, Gursel Gunes, Okan Yayar, et al. A T-cell prolymphocytic leukemia case with central nervous system involvement[J]. Int J Clin Exp Med, 2015, 8(8): 14207-14209
- [3] Bhagirathbhai R. Dholaria, Ernesto Ayala, Lubomir Sokolb, et al. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience [J]. Leukemia Research, 2018, 67: 1-5
- [4] Jordan Senchak, Peter Pickens. Brentuximab vedotin therapy for cutaneous lesions in T-prolymphocytic leukemia: a case report [J]. Hematology Reports, 2016, 8: 6593
- [5] Kamel Laribi, Pierre Lemaire, Jeremy Sandrini, et al. Advances in the understanding and management of T-cell prolymphocytic leukemia [J]. Oncotarget, 2017, 8(61): 104664-104686
- [6] Dearden C. How I treat prolymphocytic leukemia [J]. Blood, 2012, 120: 538-551
- [7] W. Wiktor-Jedrzejczak, J. Drozd-Sokolowska, D. J. Eikema, et al. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)[J]. Springer Nature, 2019, Jan 21. [Epub ahead of print]
- [8] Oliveira F, Tone LG, Simones BP, et al. Translocations t(X;14)(q28;q11) and t(Y;14)(q12;q11) in T-cell Prolymphocytic leukemia[J]. Int J Lab Hematol, 2008, 31: 453-456
- [9] Butaina Al-Musalhi, Nancy Shehata, Robin Billick. Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration [J]. Oman Medical Journal, 2016, 1: 73-76
- [10] Toyota S, Nakamura N, Dan K. Small cell variant T-cell prolymphocytic leukemia with a gamma delta immunophenotype[J]. Int J Hematol, 2005, 81: 66-68
- [11] Bryan Mitton, MD, PhD, Steven Coutre, MD, Jennifer Willert, MD, et al. A Pediatric Case of T-Cell Prolymphocytic Leukemia[J]. Pediatr Blood Cancer, 2015, 62: 1061-1062
- [12] Anna Stengel, Wolfgang Kern, Melanie Zenger, et al. Genetic Characterization of T-PLL Reveals Two Major Biologic Subgroups and JAK3 Mutations as Prognostic Marker [J]. Genes, Chromosomes & Cancer, 2016, 55: 82-94
- [13] Amit Khot. Where do we currently stand with T-cell prolymphocytic leukemia?[J]. Leukemia & Lymphoma, 2019, 22: 1-3
- [14] Garderet L, Bittencourt H, Kaliski A, et al. Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation[J]. Eur J Haematol, 2001, 66: 137-139
- [15] Rekha Chandran, S. K. Gardiner, T. S. Fenske, et al. Survival trends in T cell prolymphocytic leukemia: A SEER database analysis [J]. Leukemia & Lymphoma, 2016, 57(4): 942-944
- [16] Vishal Jayakar, Kan Cheung, Eva Yebra-Fernandez, et al. The distinctive cytological features of T-cell prolymphocytic leukemia[J]. American Journal of Hematology, 2017, 92(8): 830-832
- [17] Steven H. Swerdlow, Elias Campo, Stefano A. Pileri, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390
- [18] Dungarwalla M, Matutes E, Dearden CE, et al. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper [J]. Eur J Haematol, 2008, 80: 469-476
- [19] Paul Delgado, Phillip Starshak, Nagesh Rao, et al. A Comprehensive Update on Molecular and Cytogenetic Abnormalities in T-cell Prolymphocytic Leukemia (T-PLL) [J]. The Journal of the Association of Genetic Technologists, 2012, 38: 4
- [20] Huang Yan-ru, Qi Jun-yuan, Liu Hui-min, et al. clinical and laboratory features of T-cell prolymphocytic leukemia in China[J]. Chin J Hematol, 2013, 34: 10
- [21] Kameoka J, Takahashi N, Noji H, et al. T-cell prolymphocytic leukemia in Japan: is it a variant?[J]. Int J Hematol, 2012, 95: 660-667
- [22] Samuel Adediran, MD, Dennis Cornfeld, MD, Adam Bagg, MD, et al. An extremely indolent T-cell leukemia: an 18-year follow-up [J]. JCSO, 2016, 14: 76-78
- [23] Armin Rashidi, Stephen I. Fisher. T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus [J]. European Journal of Haematology, 2015, 95: 199-210
- [24] Clement Janot, Joffrey Feriel, Claire Borie, et al. Clinically silent indolent T-cell leukemia[J]. Clinical Case Reports, 2019, 7(1): 24-26
- [25] Krassas N, de la Mata Perez G, Jones N. Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis[J]. Ocul Immunol Inflamm, 2018, 26(3): 376-378

- emergency medicine, 2015, 33(10): 1515-1516
- [5] Baek JH, Park IH, Seo SH. An Experimental Study for Minimum Level of Decalcification to Detect the Osteolytic Bone Metastasis of Long Bone on Plain Radiography [J]. *J Bone Metab*, 2016, 23(3): 135-142
- [6] Gouse S, Karnam S, Girish HC1, et al. Forensic photography: Prospect through the lens[J]. *J Forensic Dent Sci*, 2018, 10(1): 2-4
- [7] Fu JY, Wu CF, Ko PJ, et al. Analysis of chest X-ray plain film images of intravenous ports inserted via the superior vena cava [J]. *Surg Today*, 2014, 44(8): 1513-1521
- [8] Zhao DZ, Guo Y, Sun YP, et al. Multi-detector spiral CT diagnosis of common bile duct ampullary carcinoma [J]. *Eur Rev Med Pharmacol Sci*, 2017, 21(16): 3549-3553
- [9] Benjamin R Pulley, Benjamin C Taylor, Terry Ty Fowler, et al. Utility of three-dimensional computed tomography for the surgical management of rib fractures [J]. *The journal of trauma and acute care surgery*, 2015, 78(3): 530-534
- [10] Zarelli M, Schwarz T, Puggioni A, et al. An optimized protocol for multislice computed tomography of the canine brain [J]. *Vet Radiol Ultrasound*, 2014, 55(4): 387-392
- [11] 刘洋,胡长利,石岩江,等.可吸收螺钉内固定治疗多发性肋骨骨折的临床疗效[J].现代生物医学进展,2016,16(27): 5287-5289
- [12] Harun Gunes, Elif Nisa Unlu, Ayhan Saritas. CT versus grayscale rib series for the detection of rib fracture [J]. *The American journal of emergency medicine*, 2015, 33(10): 1515-1516
- [13] Zhang Y, Zhou Y, Yang X, et al. Thin slice three dimensional (3D) reconstruction versus CT 3D reconstruction of human breast cancer [J]. *Indian J Med Res*, 2013, 137(1): 57-62
- [14] Igor Jeroukhimov, Yehuda Hershkovitz, Itay Wiser, et al. When Should Abdominal Computed Tomography Be Considered in Patients with Lower Rib Fractures? [J]. *The Journal of emergency medicine*, 2017, 52(5): 609-614
- [15] Li Y, Song J, Lin N, et al. Computed tomography scan is superior to x-ray plain film in the diagnosis of gastrointestinal tract perforation [J]. *Am J Emerg Med*, 2015, 33(3): 480.e3-5
- [16] 张雷,臧海军,庞国庆,等.高频超声与X线和CT三维成像在肋骨骨折诊断中的比较研究[J].河北医药,2018,40(3): 437-439
- [17] 李明亮,邓光,刘忠岐,等.DR摄影与双能量减影对隐匿性肋骨骨折的影像学研究[J].中国临床研究,2014,27(3): 337-338
- [18] 杨泽峰,钟建平,杨立光.多层螺旋CT及多维重建技术对隐匿性肋骨骨折的诊断价值分析[J].浙江临床医学,2018,20(1): 153-154
- [19] 马锦怡,李鹏,喻国艳,等.基于CT图像后处理技术人体骨关节系统三维图像在影像解剖学学习中的应用价值[J].海南医学,2018,29(14): 1991-1993
- [20] Khojastepour L, Mohammadzadeh S, Jazayeri M, et al. In vitro Evaluation of the Relationship between Gray Scales in Digital Intraoral Radiographs and Hounsfield Units in CT Scans[J]. *J Biomed Phys Eng*, 2017, 7(3): 289-298
- [21] Wen Z, Yao F, Wang Y. 64-Slice spiral computed tomography and three-dimensional reconstruction in the diagnosis of cystic pancreatic tumors[J]. *Exp Ther Med*, 2016, 11(4): 1506-1512
- [22] Alyaev YG, Dzeranov NK, Khokhlachev SB, et al. A new method of evaluation of split renal function based on contrast-enhanced multislice spiral computed tomography [J]. *Urologiiia*, 2018, 13 (2): 26-33
- [23] Mitev K, Neziri D, Stoicovski E, et al. Surgical plate fixation of multiple rib fractures:a case report [J]. *J Med Case Rep*, 2018, 12(1): 150
- [24] Benyan AS. Blunt chest trauma:possibilities to stabilize multiple and floating ribs fractures[J]. *Khirurgiia (Mosk)*, 2017, 10(8): 69-74
- [25] 陈建乐,邱其良,祝华强,等.16层螺旋CT、DR胸片对肋骨骨折的诊断价值的比较分析[J].现代医用影像学,2017,26(3): 691-692, 695
- [26] 蔡清清,周理余,王淑珍.16层螺旋CT与DR检查肋骨骨折临床应用价值分析[J].医学影像学杂志,2016,26(11): 2135-2137
- [27] 宋长利,夏楠.16层螺旋CT三维重建在股骨粗隆间骨折治疗中的应用[J].中国CT和MRI杂志,2016,14(1): 123-125
- [28] At'kova EL, Tomashevskii IO, Luchshev AI, et al. Single-photon emission computed tomography in combination with X-ray computed tomography in the study of lacrimal passages. First results [J]. *Vestn Rentgenol Radiol*, 2014, 16(2): 26-30
- [29] 张倩,于洋,孙正君,等.颞骨骨折与正常骨缝在16排螺旋CT中的鉴别[J].中国煤炭工业医学杂志,2017,20(1): 4-7
- [30] 尹建章,秦家骏,陈先震.16层螺旋CT对可疑颅骨骨折的诊断价值[J].同济大学学报(医学版),2018,39(3): 110-113, 127

(上接第 3852 页)

- [26] Beenu Thakral, Sa A. Wang. T-cell prolymphocytic leukemia negative for surface CD3 and CD45[J]. *Blood*, 2018, 132(1): 111
- [27] Naveen Kakkar, Nalini Calton, M. Joseph John. T Cell Prolymphocytic Leukemia (T-PLL): Cutaneous Involvement in an Uncommon Leukemia[J]. *Indian J Hematol Blood Transfus*, 2018, 34(3): 573-574
- [28] Moussab Damlaj, Nanna H. Sulai, Jennifer L. Oliveira, et al. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience[J]. *Clinical Lymphoma, Myeloma & Leukemia*, 2015, 11: 699-704
- [29] Yi Sun, Guilin Tang, Zhihong Hu, et al. Comparison of karyotyping, TCL1 fluorescence in situ hybridisation and TCL1 immunohistochemistry in T cell prolymphocytic leukaemia[J]. *J Clin Pathol*, 2017, 0: 1-7
- [30] Krishnan B, Matutes E, Dearden C. Prolymphocytic Leukemias[J]. *Jseminoncol*, 2006, 33(2): 257-263
- [31] Mohammad A. Abdulla, Firyal Ibrahim, Mahmoud Aldapt, et al. Prolymphocytic Leukemia, a rare disease, case presentation with typical pathological findings and review of management [J]. *International Journal of Current Research*, 2018, 3: 49